HEPARIN 5000 IU/ml Price

Overview

Welcome to Dwaey, specifically on HEPARIN 5000 IU/ml page.
This medicine contains an important and useful components, as it consists of
Heparin sodiumis available in the market in concentration

Name

Heparin Sodium

Precaution

Monitor platelet counts. Discontinue treatment if thrombocytopenia occurs. Hypersensitivity, elderly, pregnancy. Lactation: Not excreted in breast milk; compatible

Indication

Atrial fibrillation, Acute coronary syndrome, Unstable angina, Pulmonary embolism, Thromboembolism, Deep-vein thrombosis, Cardiopulmonary bypass, Hemofiltration, Peripheral arterial embolism

Contra indication

Patients predisposed to active bleeding including thrombocytopenia, peptic ulcer disease, cerebrovascular disorders, haemorrhagic blood disorders, bacterial endocarditis, severe hypertension, oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage, abdominal or thoracic bleeding into closed space, severe traumatic bleed, hepatic, renal, splenic or arterial injury, severe haemostatic defect, arterial thrombosis with heparin-associated thrombocytopenia. IM admin.

Side Effect

>10% Heparin-induced thrombocytopenia, possibly delayed (10-30% ) Frequency Not Defined Mild pain,Hematoma,Hemorrhage,Local irritation,Erythema,Injection site ulcer (after deep SC injection),Increased liver aminotransferase,Anaphylaxis,Immune hypersensitivity reaction,Osteoporosis (long-term, high-dose use) Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding.

Pregnancy Category ID

3

Mode of Action

Heparin increases the inhibitory action of antithrombin III (AT III) on clotting factors XIIa, XIa, IXa, Xa and thrombin. This inhibits the conversion of prothrombin to thrombin and fibrinogen to fibrin. It also inhibits platelet function. It may reduce the activity of ATIII at very high doses.

Interaction

Enhanced anticoagulant effect w/ other drugs affecting platelet function or the coagulation system (e.g. platelet aggregation inhibitors, thrombolytic agents, salicylates, NSAIDs, vit K antagonists, dextrans, activated protein C). Decreased anticoagulant effect w/ gyceryl trinitrate infusion. Increased risk of hyperkalaemia w/ ACE inhibitors or angiotensin II antagonists.

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration